Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives

References

• RosamondWFlegalKFurieKHeart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics SubcommitteeCirculation20081174e25e14618086926
   PubMed Web of Science ®Google Scholar
• VolpeMAldermanMHFurbergCDBeyond hypertension toward guidelines for cardiovascular risk reductionAm J Hypertens20041117(11 Pt 1)1068107415533736
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics2242008Accessed on Jan 10, 2009. Available from: http://www.cdc.gov/nchs/
   Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet2002360932672212114036
   PubMed Web of Science ®Google Scholar
• SeverPSDahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336193641149115812686036
   PubMed Web of Science ®Google Scholar
• TurnbullFEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet2004364943568569615325833
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• PettittDKarterAJPengTYThe impact of concurrent dyslipidemia and diabetes on hypertension management and goal attainmentVancouver, CanadaPoster presentation at the 26th Annual Meeting of the Society of General Internal Medicine2003
   Google Scholar
• EUROASPIRE I and II GroupEuropean Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce EventsLancet20013579261995100111293642
   PubMedGoogle Scholar
• PearsonTALauroraIChuHKafonekSThe lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goalsArch Intern Med2000160445946710695686
   PubMed Web of Science ®Google Scholar
• InsullWThe problem of compliance to cholesterol altering therapyJ Intern Med199724143173259159603
   PubMed Web of Science ®Google Scholar
• ChapmanRHBennerJSPetrillaAAPredictors of adherence with antihypertensive and lipid-lowering therapyArch Intern Med2005165101147115215911728
   PubMedGoogle Scholar
• SchroederKFaheyTEbrahimSHow can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trialsArch Intern Med2004164772273215078641
   PubMedGoogle Scholar
• BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: a meta-analysisAm J Med2007120871371917679131
   PubMed Web of Science ®Google Scholar
• KrumHCritical assessment of calcium antagonistsAust Fam Physician19972678418459232924
   PubMedGoogle Scholar
• ZhangXHintzeTHAmlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agentCirculation19989765765809494028
   PubMed Web of Science ®Google Scholar
• JukemaJWvan der HoornJWAmlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapyExpert Opin Pharmacother20045245946814996641
   PubMed Web of Science ®Google Scholar
• MasonRPMarchePHintzeTHNovel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipineArterioscler Thromb Vasc Biol200323122155216314512371
   PubMed Web of Science ®Google Scholar
• ChungMCalcagniAGluePBramsonCBioavailability of amlodipine besylate/atorvastatin calcium combination tabletJ Clin Pharmacol20064691030103716920898
   PubMed Web of Science ®Google Scholar
• BattlemanDPetersonEEstimated prevalence of comorbid hypertension and dyslipidemia and therapeutic goal attainment among US adults in 2000, utilizing data from the National Health and Nutrition Examination Survey (NHANES III)J Manag Care Pharm200410186
   Google Scholar
• BlankRLaSalleJReevesRMaroniJTarasenkoLSunFSingle-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study)J Clin Hypertens (Greenwich)20057526427315886529
   PubMedGoogle Scholar
• ChungMCalcagniAGluePBramsonCEffect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tabletJ Clin Pharmacol200646101212121616988211
   PubMed Web of Science ®Google Scholar
• PrestonRAHarveyPHerfertOReduction in Framingham cardiovascular risk with concomitant treatment of hypertension/dyslipidemia with amlodipine/atorvastatinAm J Hypertens200518A226
   Web of Science ®Google Scholar
• MesserliFHBakrisGLFerreraDEfficacy and safety of coad-ministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trialJ Clin Hypertens (Greenwich)200688571581; quiz 582–583.16896273
   PubMedGoogle Scholar
• PrestonRASunFTarasenkoLSafety and tolerability of coad-ministered amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia in the Respond studyAm J Hypertens200518A92A93
   Web of Science ®Google Scholar
• MasonRPA rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidenceCurr Drug Targets Cardiovasc Haematol Disord20055648950116503869
   PubMedGoogle Scholar
• CohnJNeutelJHoustonMEarly improvements in vascular compliance following coadministration of amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia. The Avalon Arterial Wall Compliance (AWC) trialSan Francisco, CAProgram and abstracts from the 20th Annual Scientific Meeting of the American Society of HypertensionMay 14–182005
   Google Scholar
• LeibovitzEBeniashviliMZimlichmanRFreimanAShargorodskyMGavishDTreatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patientsAm J Hypertens200316(9 Pt 1)71571812944027
   PubMed Web of Science ®Google Scholar
• FogariRPretiPZoppiAEffects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patientsEur J Clin Pharmacol2006621081782216896785
   PubMedGoogle Scholar
• FogariRDerosaGLazzariPEffect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistanceAm J Hypertens200417982382715363826
   PubMed Web of Science ®Google Scholar
• DelsingDJJukemaJWvan de WielMADifferential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE * 3-Leiden transgenic miceJ Cardiovasc Pharmacol2003421637012827028
   PubMed Web of Science ®Google Scholar
• MasonRPWalterMFDayCAJacobRFIntermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actionsAm J Cardiol2005965A11F23F
   PubMed Web of Science ®Google Scholar
• JukemaJWZwindermanAHvan BovenAJEvidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study GroupArterioscler Thromb Vasc Biol19961634254308630669
   PubMedGoogle Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA2002288232981299712479763
   PubMed Web of Science ®Google Scholar
• JuliusSWeberMAKjeldsenSEThe Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapyHypertension200648338539116864741
   PubMed Web of Science ®Google Scholar
• DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet2005366948989590616154016
   PubMed Web of Science ®Google Scholar
• PoulterNRWedelHDahlofBRole of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Lancet2005366948990791316154017
   PubMed Web of Science ®Google Scholar
• WilliamsBO’RourkeMThe Conduit Artery Functional Endpoint (CAFE) study in ASCOTJ Hum Hypertens200115Suppl 1S69S7311685915
   PubMed Web of Science ®Google Scholar
• PackerMO’ConnorCMGhaliJKEffect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study GroupN Engl J Med199633515110711148813041
   PubMed Web of Science ®Google Scholar
• PittBByingtonRPFurbergCDEffect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT InvestigatorsCirculation2000102131503151011004140
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMLibbyPEffect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trialJAMA2004292182217222515536108
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350151495150415007110
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med2005352141425143515755765
   PubMed Web of Science ®Google Scholar
• ShepherdJBarterPCarmenaREffect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) studyDiabetes Care20062961220122616731999
   PubMed Web of Science ®Google Scholar
• PedersenTRFaergemanOKasteleinJJHigh-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialJAMA2005294192437244516287954
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMSchoenhagenPEffect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trialJAMA200429191071108014996776
   PubMed Web of Science ®Google Scholar
• KorenMJHunninghakeDBClinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance studyJ Am Coll Cardiol20044491772177915519006
   PubMed Web of Science ®Google Scholar
• AthyrosVGMikhailidisDPPapageorgiouAARelationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) StudyCurr Med Res Opin20042091385139215383187
   PubMed Web of Science ®Google Scholar
• ErdineSRoYMTseHFGemini-AALA InvestigatorsSingle-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study)J Hum Hypertens200923319621018800143
   PubMed Web of Science ®Google Scholar
• HobbsFDGensiniGManciniGBCan combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)Int J Cardiol2006110224225016338012
   PubMed Web of Science ®Google Scholar
• FlackJMVictorRWatsonKImproved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trialMayo Clin Proc2008831354518174006
   PubMed Web of Science ®Google Scholar
• PrestonRAHarveyPHerfertOA randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trialJ Clin Pharmacol200747121555156918048574
   PubMed Web of Science ®Google Scholar
• SeverPDahlofBPoulterNPotential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes TrialEur Heart J200627242982298817145722
   PubMed Web of Science ®Google Scholar
• LindgrenPBuxtonMKahanTAmlodipine +atorvastatin is cost effective compared to atenolol +atorvastatin, amlodipine or atorvastatin alone: the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)Eur Heart J200728Abstr Suppl85717303589
   PubMedGoogle Scholar
• SmithTW CSTangSSKClinical and economic consequences of single pill combination of amlodipine/atorvastatin compared with a two-pill regimen in hypertension patients with additional cardiovascular risk factorsEur Heart J200728Abstr Suppl85717303589
   PubMedGoogle Scholar
• TattiPPahorMByingtonRPOutcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDMDiabetes Care19982145976039571349
   PubMed Web of Science ®Google Scholar
• DeziiCMA retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertensionManag Care200099Suppl2611729417
   PubMedGoogle Scholar
• EronJJYetzerESRuanePJEfficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infectionAIDS20001467168110807190
   PubMed Web of Science ®Google Scholar
• GeiterLJO’BrienRJCombsDLSniderDEJrUnited States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamideTubercle1987682 Suppl41463318048
   PubMedGoogle Scholar
• MelikianCWhiteTJVanderplasAAdherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapyClin Ther20022446046711952029
   PubMed Web of Science ®Google Scholar
• NDC dataset (personal communication from Novartis – November 2005).
   Google Scholar
• SuWJPerngRPFixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-upInt J Tuberc Lung Dis200261029103212475151
   PubMedGoogle Scholar
• TaylorAAShoheiberOAdherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapyCongest Heart Fail2003932433214688505
   PubMedGoogle Scholar
• PatelBVLeslieRSFoodyJMAdherence with single pill amlodipine/atorvastatin vs a two pill regimenVasc Health Risk Manage200843673681
   PubMedGoogle Scholar